Press Release June 25, 2020

Capital Markets Team Advises Underwriters of Upsized $253 Million Repare Therapeutics IPO

The Life Sciences Capital Markets team advised the underwriters of Repare Therapeutics’ (Nasdaq: RPTX) upsized $253 million initial public offering. Repare sold 12,650,000 common shares, which includes the exercise in full of the underwriters’ option to purchase an additional 1,650,000 common shares, at a public offering price of $20.00 per share.  
Repare is a leading precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The company utilizes its genome-wide, CRISPR-enabled SNIPRx® platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair.
The Goodwin team was led by Mitch Bloom, Seo Salimi, Will Magioncalda and Tom Schaad and included Julie Tibbets, Elizabeth Mulkey, Duncan Greenhalgh, Olivia Uitto, Roger Cohen, Dan Karelitz, Sarah Bock, Ettore Santucci, and Peter LaVigne.
For more details, read the press release and articles in Xconomy, Endpoints, and Seeking Alpha.